Our approach is applied on the laborious task of tracking a high number of bone lesions in full-body baseline and follow-up [68Ga]Ga- or [18F]F-PSMA PET/CT scans after two cycles of [177Lu]Lu-PSMA therapy of metastatic castration resistant prostate cancer patients. This evidence concerns the gene FOLH1 and prostate carcinoma.